GO:0016279 protein-lysine N-methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016279 describes the enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to the epsilon-amino group of a lysine residue in a protein substrate.
• This activity is carried out by protein lysine methyltransferases (PKMTs), a large family of enzymes that include SUV39H2, G9a, SMYD2, SETDB1, SUV420H1, and HEMK2.
• PKMTs regulate diverse cellular processes such as autophagy, retroelement silencing, chromatin organization, and gene expression.
• Dysregulated protein lysine methylation is implicated in cancer, intervertebral disc degeneration, and other diseases, making PKMTs attractive drug targets.
• Small-molecule inhibitors of PKMTs such as G9a and SUV39H2 have been developed and characterized, highlighting their therapeutic potential.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential tools for dissecting the causal roles of PKMTs in health and disease.
Description
Protein-lysine N-methyltransferase activity (GO:0016279) is a fundamental enzymatic function that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the epsilon-amino group of a lysine residue within a protein substrate. This post-translational modification, known as lysine methylation, is a key regulator of protein function, stability, and interactions, and it plays critical roles in diverse biological processes including chromatin remodeling, transcriptional regulation, and signal transduction. The enzymes responsible for this activity, protein lysine methyltransferases (PKMTs), are a large and diverse family of proteins that often contain a conserved SET domain or other catalytic folds. Researchers study GO:0016279 because dysregulation of lysine methylation is linked to numerous human diseases, including cancer, neurodegeneration, and intervertebral disc degeneration. For example, the methyltransferase SUV39H2 methylates PPP1CA, disrupting TFEB-dependent autophagy and promoting intervertebral disc degeneration. Somatic cancer mutations in SUV420H1 modulate its catalytic activity, suggesting a direct role in tumorigenesis. Moreover, PKMTs such as G9a and SMYD2 are considered promising therapeutic targets, and small-molecule inhibitors are being actively developed. Understanding the molecular mechanisms, substrate specificity, and regulation of protein-lysine N-methyltransferase activity is therefore essential for both basic biology and translational research. This article provides a comprehensive overview of GO:0016279, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and the experimental methods used to study it. We also highlight how CRISPR-based models and EDITGENE services can accelerate research in this field.
protein-lysine N-methyltransferase activity At A Glance
| GO ID | GO:0016279 |
|---|---|
| GO term | protein-lysine N-methyltransferase activity |
| Ontology | molecular_function |
| Synonym | protein lysine methylase activity, protein (lysine) methyltransferase activity |
| Major function | Catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to the epsilon-amino group of a lysine residue in a protein substrate |
| EC number | 2.1.1.43 |
| Substrates | Proteins containing lysine residues; methyl donor S-adenosyl-L-methionine (SAM) |
| Cofactors | S-adenosyl-L-methionine (SAM) as methyl donor |
| Localization | Nucleus, cytoplasm, and other cellular compartments depending on the specific enzyme |
What Is GO:0016279?
Protein-lysine N-methyltransferase activity (GO:0016279) is defined as the catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to the epsilon-amino group of a lysine residue in a protein substrate. This activity is synonymous with protein lysine methylase activity and protein (lysine) methyltransferase activity. It is a molecular function that modifies proteins post-translationally, thereby altering their chemical properties, interactions, and biological functions.
Why Is protein-lysine N-methyltransferase activity Important in Cell Biology?
Protein-lysine N-methyltransferase activity is critically important because it governs a wide array of cellular processes through the post-translational modification of proteins. Lysine methylation can alter protein-protein interactions, enzymatic activity, subcellular localization, and stability, thereby influencing gene expression, DNA repair, cell cycle progression, and autophagy. Dysregulation of this activity is associated with cancer, neurodegeneration, and intervertebral disc degeneration, making PKMTs key targets for drug discovery. Furthermore, the development of specific inhibitors and the use of CRISPR models to study PKMTs are advancing our understanding of their roles in health and disease.
• Regulates chromatin structure and gene expression through histone methylation.
• Controls autophagy and lysosomal function via methylation of non-histone proteins such as PPP1CA.
• Silences retroelements and maintains genome stability through SETDB1-mediated methylation.
• Modulates cancer cell proliferation and survival; mutations in PKMTs are found in various tumors.
• Plays a role in intervertebral disc degeneration by disrupting TFEB-dependent autophagy.
• Serves as a target for small-molecule inhibitors with therapeutic potential in cancer and other diseases.
• Influences protein stability and interactions through methylation of lysine residues.
• Exhibits distinct substrate specificities, as shown for HEMK2 and SUV39H2.
• Can be studied quantitatively using SILAC-based proteomics to profile activity.
• Provides a paradigm for understanding enzyme-substrate recognition and catalysis.
Molecular Mechanism of protein-lysine N-methyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme first grabs the target protein and the methyl donor molecule.
Protein lysine methyltransferases (PKMTs) recognize specific lysine residues within substrate proteins through their catalytic domains, often SET domains. For example, SUV39H2 specifically methylates PPP1CA at a particular lysine, and this interaction is critical for its function in autophagy regulation. The substrate binding pocket accommodates the target lysine and positions it for methyl transfer. Structural and biochemical studies have revealed that PKMTs exhibit distinct substrate specificities; for instance, HEMK2 can methylate both glutamine and lysine residues, with different preferences. The binding of S-adenosyl-L-methionine (SAM) is also essential, as it provides the methyl group.
Catalytic Methyl Transfer
In simple terms: The enzyme transfers a methyl group from SAM onto the lysine side chain of the target protein.
The catalytic mechanism involves the nucleophilic attack of the epsilon-amino group of the target lysine on the methyl group of SAM, resulting in the formation of S-adenosyl-L-homocysteine (SAH) and a methylated lysine residue. This reaction is facilitated by a conserved catalytic domain, often a SET domain, which positions the substrates and stabilizes the transition state. The activity can be modulated by mutations; for example, somatic cancer mutations in SUV420H1 alter its catalytic activity, affecting methylation of its substrates. The reaction is highly specific and can result in mono-, di-, or tri-methylation of the lysine residue, depending on the enzyme and substrate.
Cofactors and Cofactor Binding
In simple terms: SAM is the universal methyl donor that powers the reaction.
S-adenosyl-L-methionine (SAM) is the essential cofactor and methyl donor for all protein-lysine N-methyltransferase reactions. SAM binds to a conserved Rossmann-fold or SET domain pocket, and its binding affinity can influence enzyme activity. The byproduct S-adenosyl-L-homocysteine (SAH) is a potent inhibitor of many PKMTs, and the SAM/SAH ratio in cells can regulate methylation levels. Some PKMTs may also require additional cofactors or post-translational modifications for full activity, but SAM is universally required.
Regulation of Activity
In simple terms: The enzyme's activity can be turned on or off by other molecules or modifications.
Protein-lysine N-methyltransferase activity is regulated at multiple levels, including enzyme expression, post-translational modifications, and interaction with regulatory proteins. For example, the activity of SUV39H2 can be modulated by its own methylation or by interacting partners. Small-molecule inhibitors such as those targeting G9a can block methyltransferase activity, demonstrating that pharmacological regulation is possible. Additionally, mutations in PKMTs can lead to constitutive activation or loss of function, as seen in cancer-associated variants of SUV420H1. The cellular levels of SAM and SAH also influence activity, linking methylation to metabolic status.
Substrate Specificity and Product Diversity
In simple terms: Different enzymes methylate different proteins, and the number of methyl groups added can vary.
PKMTs exhibit a wide range of substrate specificities. Some enzymes methylate histone proteins, while others target non-histone proteins such as PPP1CA, p53, or SMYD2 substrates. The degree of methylation (mono-, di-, or tri-methylation) can have distinct functional consequences. For instance, SMYD2-mediated methylation of specific substrates has been profiled using SILAC-based proteomics, revealing multiple targets. HEMK2 can methylate both glutamine and lysine residues, expanding the repertoire of methylation beyond lysine. This diversity allows PKMTs to fine-tune cellular signaling and gene expression.
Key Genes Involved in GO:0016279 protein-lysine N-methyltransferase activity
The following genes encode protein lysine methyltransferases or related proteins that carry out GO:0016279 activity and have been experimentally characterized.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SUV39H2 | Methylates PPP1CA and histones; regulates autophagy and chromatin | Implicated in intervertebral disc degeneration; studied for substrate specificity |
| G9a (EHMT2) | Histone H3K9 methyltransferase; transcriptional repression | Target for small-molecule inhibitors; role in cancer and development |
| SMYD2 | Methylates histone and non-histone proteins (e.g., p53, RB) | Profiled using SILAC proteomics; potential cancer target |
| SETDB1 | Histone H3K9 methyltransferase; silences retroelements | Critical for genome stability and immune response |
| SUV420H1 | Histone H4K20 methyltransferase | Somatic cancer mutations modulate activity; role in tumorigenesis |
| HEMK2 (N6AMT1) | Methylates glutamine and lysine residues in proteins | Unusual dual specificity; studied for substrate recognition |
| EZH2 | Histone H3K27 methyltransferase; Polycomb repressive complex | Well-known cancer target; not directly cited but related family |
| SETD2 | Histone H3K36 methyltransferase | Linked to renal cell carcinoma and other cancers |
| DOT1L | Histone H3K79 methyltransferase | Involved in leukemia; target for inhibitors |
| PRMT family | Protein arginine methyltransferases (not lysine-specific but related) | Broader methylation research |
| NSD1 | Histone H3K36 methyltransferase | Implicated in Sotos syndrome and cancer |
| ASH1L | Histone H3K36 methyltransferase | Role in development and leukemia |
| SETD7 | Histone H3K4 methyltransferase | Regulates transcription and metabolism |
| SMYD3 | Histone H3K4 methyltransferase | Overexpressed in cancers; drug target |
| WHSC1 (NSD2) | Histone H3K36 methyltransferase | Multiple myeloma target |
| SUV39H1 | Histone H3K9 methyltransferase | Heterochromatin formation; cancer |
| EHMT1 | Histone H3K9 methyltransferase | Kleefstra syndrome; neuronal function |
| PRDM9 | Histone H3K4 methyltransferase | Meiotic recombination hotspots |
How Is protein-lysine N-methyltransferase activity Regulated?
Protein-lysine N-methyltransferase activity is regulated at multiple levels. Enzyme abundance is controlled by transcription, translation, and protein degradation. Post-translational modifications of the enzymes themselves, such as phosphorylation, ubiquitination, and methylation, can modulate their activity. Interaction with regulatory subunits or accessory proteins can also influence substrate specificity and catalytic rate. For example, the activity of SUV39H2 is regulated by its own methylation status and by interacting proteins. Small-molecule inhibitors can block activity, and cellular levels of SAM and SAH, the methyl donor and byproduct, respectively, provide metabolic regulation. Additionally, mutations in PKMTs can lead to altered activity, as seen in cancer-associated variants of SUV420H1.
protein-lysine N-methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SUV39H2 | Intervertebral disc degeneration | Knockout or point-mutation in cell lines; autophagy assays |
| SUV420H1 | Cancer (somatic mutations) | Knock-in of cancer mutations; methyltransferase activity assays |
| SETDB1 | Retroelement silencing, genome stability | Knockout cells; retroelement expression analysis |
| G9a (EHMT2) | Cancer, transcriptional repression | Inhibitor treatment; knockout models |
| SMYD2 | Cancer, p53 regulation | Overexpression and knockout; SILAC proteomics |
Cancer
Dysregulation of protein-lysine N-methyltransferase activity is frequently observed in cancer. Somatic mutations in the SUV420H1 gene modulate its catalytic activity, potentially contributing to tumorigenesis. Overexpression or aberrant activity of PKMTs such as G9a, EZH2, and SMYD2 has been linked to various cancers, making them attractive targets for small-molecule inhibitors. For instance, G9a inhibitors have been designed and synthesized, showing promise in preclinical models. The role of PKMTs in cancer is further supported by their ability to methylate histones and non-histone proteins involved in cell cycle control and apoptosis.
Intervertebral Disc Degeneration
Lysine methylation of PPP1CA by the methyltransferase SUV39H2 disrupts TFEB-dependent autophagy and promotes intervertebral disc degeneration. This finding establishes a direct link between PKMT activity and a degenerative musculoskeletal disease. The study highlights how aberrant methylation of a non-histone substrate can impair cellular homeostasis and contribute to disease pathology.
Genome Stability and Retroelement Silencing
SETDB1-mediated silencing of retroelements through histone methylation is critical for maintaining genome stability. Loss of SETDB1 activity leads to retroelement reactivation and subsequent immune responses, which can contribute to autoimmune diseases and cancer. This demonstrates the importance of protein-lysine N-methyltransferase activity in safeguarding the genome.
Neurological and Developmental Disorders
While not extensively covered by the provided citations, PKMTs such as EHMT1 are associated with Kleefstra syndrome, a neurodevelopmental disorder. The broader family of lysine methyltransferases plays roles in neuronal function and development, and their dysregulation may contribute to neurodegeneration. However, specific citations for these links are not included in this article's reference list.
From protein-lysine N-methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PKMT activity affect autophagy? | Knockout of SUV39H2 in cell lines; monitor TFEB and autophagy markers |
| How do cancer mutations alter PKMT activity? | Point mutation knock-in of SUV420H1 variants; measure methylation |
| What are the substrates of a specific PKMT? | Overexpression of tagged PKMT; SILAC-based proteomics |
| Can a PKMT inhibitor block methylation in cells? | Treatment with G9a inhibitors; western blot for methylated substrates |
| What is the role of SETDB1 in retroelement silencing? | Knockout of SETDB1; RNA-seq for retroelement expression |
| How does HEMK2 discriminate between glutamine and lysine? | Point mutations in catalytic domain; in vitro methylation assays |
How to Study the protein-lysine N-methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| SILAC-based proteomics | Global methylation changes on proteins | Profiling PKMT substrates and activity |
| In vitro methyltransferase assay | Enzymatic activity and kinetics | Characterizing PKMT specificity and mutants |
| Western blot with methyl-specific antibodies | Levels of specific methylated proteins | Validating methylation in cells |
| CRISPR knockout | Loss of gene function | Studying PKMT role in disease models |
| CRISPR knock-in | Introduction of specific mutations | Modeling cancer-associated mutations |
| RNA-seq | Transcriptional changes | Assessing retroelement silencing |
| Small-molecule inhibitor treatment | Inhibition of enzyme activity | Therapeutic target validation |
| Immunoprecipitation | Protein-protein interactions | Identifying PKMT complexes |
Quantitative Proteomics for Methylation Profiling
SILAC-based proteomics allows global profiling of protein lysine methylation. Olsen et al. used this approach to quantitatively profile the activity of SMYD2, identifying multiple substrates and methylation sites. This method is powerful for discovering new targets and understanding the specificity of PKMTs.
In Vitro Methyltransferase Assays
Recombinant PKMTs can be incubated with substrate proteins and SAM to measure methyltransferase activity. These assays are used to determine kinetic parameters, substrate specificity, and the effect of mutations. For example, the activity and specificity of SUV39H2 were characterized using such assays, and HEMK2's dual specificity was dissected.
CRISPR-Based Genetic Models
CRISPR/Cas9 technology enables the generation of knockout, point mutation, knock-in, and overexpression models to study PKMT function. Knockout of SUV39H2 revealed its role in intervertebral disc degeneration, while knock-in of cancer mutations in SUV420H1 helped assess their impact on catalytic activity. These models are essential for establishing causality.
Small-Molecule Inhibitor Studies
Inhibitors of PKMTs, such as G9a inhibitors, are valuable tools to probe function and therapeutic potential. Liu et al. designed and synthesized 2,4-diamino-7-aminoalkoxy-quinazolines as G9a inhibitors, demonstrating their ability to block methylation in cells. Such studies inform drug development and target validation.
How CRISPR Can Be Used to Study GO:0016279 protein-lysine N-methyltransferase activity
Knockout
CRISPR knockout of PKMT genes is used to completely abolish their methyltransferase activity. For example, knockout of SUV39H2 demonstrated its role in autophagy and intervertebral disc degeneration. Knockout of SETDB1 revealed its essential function in silencing retroelements. These models are crucial for loss-of-function studies.
Point Mutation
Point mutations can be introduced into PKMT catalytic domains to dissect specific residues required for activity or substrate recognition. For instance, somatic cancer mutations in SUV420H1 were modeled by point mutation to assess their impact on catalytic activity. Such models help distinguish between catalytic and non-catalytic functions.
Knock-in
Knock-in of tagged or mutant PKMTs allows for precise tracking and functional analysis. For example, knock-in of a tagged SMYD2 could facilitate proteomic profiling of its substrates. Knock-in of disease-associated mutations can model their effects in a physiological context.
Overexpression
Overexpression of PKMTs is used to study gain-of-function effects and to identify substrates. Overexpression of SMYD2 followed by SILAC proteomics led to the identification of multiple methylation targets. Overexpression can also be combined with inhibitor treatment to validate specificity.
How EDITGENE Supports protein-lysine N-methyltransferase activity Research
Researchers studying protein-lysine N-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. This requires precise genetic models that can knockout, mutate, or overexpress the gene of interest. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such research.
Contact EDITGENE today to design your custom CRISPR model for protein-lysine N-methyltransferase activity research.
Frequently Asked Questions About protein-lysine N-methyltransferase activity
What is protein-lysine N-methyltransferase activity?
It is the enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to the epsilon-amino group of a lysine residue in a protein substrate, as defined by GO:0016279.
What genes are involved in protein-lysine N-methyltransferase activity?
Key genes include SUV39H2, G9a (EHMT2), SMYD2, SETDB1, SUV420H1, and HEMK2, among others.
How is protein-lysine N-methyltransferase activity regulated?
It is regulated by enzyme expression, post-translational modifications, interaction partners, and cellular levels of SAM and SAH.
What diseases are associated with protein-lysine N-methyltransferase activity?
Dysregulation is linked to cancer, intervertebral disc degeneration, and genome instability through retroelement silencing.
What methods are used to study protein-lysine N-methyltransferase activity?
Common methods include SILAC-based proteomics, in vitro methyltransferase assays, western blotting, and CRISPR-based genetic models.
Can protein-lysine N-methyltransferase activity be inhibited?
Yes, small-molecule inhibitors such as G9a inhibitors have been developed and shown to block methylation.
What is the role of SUV39H2 in disease?
SUV39H2 methylates PPP1CA, disrupting TFEB-dependent autophagy and promoting intervertebral disc degeneration.
How do mutations in PKMTs contribute to cancer?
Somatic mutations, such as those in SUV420H1, can modulate catalytic activity and potentially drive tumorigenesis.
What is the substrate specificity of HEMK2?
HEMK2 can methylate both glutamine and lysine residues, exhibiting distinct specificities.
How can CRISPR be used to study protein-lysine N-methyltransferase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of PKMT genes to study their function and causality.
Conclusion
Protein-lysine N-methyltransferase activity (GO:0016279) is a crucial molecular function that regulates diverse cellular processes through post-translational methylation of lysine residues. Its dysregulation is implicated in cancer, intervertebral disc degeneration, and genome instability, making it a vibrant area of research. The availability of CRISPR-based models and small-molecule inhibitors provides powerful tools to dissect the mechanisms and therapeutic potential of PKMTs. EDITGENE offers comprehensive services to support these studies, from custom cell line generation to bioinformatics analysis.
References
- 1. Liang H et al.. 2023. Lysine methylation of PPP1CA by the methyltransferase SUV39H2 disrupts TFEB-dependent autophagy and promotes intervertebral disc degeneration.. Cell Death Differ 30(9):2135-2150 PMID: 37605006
- 2. Li Y et al.. 2023. Protein Lysine Methyltransferases Inhibitors.. Curr Med Chem 30(27):3060-3089 PMID: 36043747
- 3. Bröhm A et al.. 2019. Somatic Cancer Mutations in the SUV420H1 Protein Lysine Methyltransferase Modulate Its Catalytic Activity.. J Mol Biol 431(17):3068-3080 PMID: 31255706
- 4. Fukuda K et al.. 2020. SETDB1-Mediated Silencing of Retroelements.. Viruses 12(6) PMID: 32486217
- 5. Olsen JB et al.. 2016. Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.. Mol Cell Proteomics 15(3):892-905 PMID: 26750096
- 6. Weirich S et al.. 2024. Distinct specificities of the HEMK2 protein methyltransferase in methylation of glutamine and lysine residues.. Protein Sci 33(2):e4897 PMID: 38284488
- 7. Schuhmacher MK et al.. 2015. Activity and specificity of the human SUV39H2 protein lysine methyltransferase.. Biochim Biophys Acta 1849(1):55-63 PMID: 25459750
- 8. Liu F et al.. 2010. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.. J Med Chem 53(15):5844-57 PMID: 20614940
